AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Stock Quotes and News

AMAG Pharmaceuticals, Inc. (AMAG) 25.08 0.13

Price Open:	24.91	Day's Range:	0.00000 - 26.25000
Price Close:	24.93	52wk Range:	0.00000 - 26.25000
Price Day Change:	0.13	Volume:	111,240
Price % Change:	0.52	Market Cap:	540.6M
Bid:	25.05000	PE Ratio:	0
Ask:	25.08000	EPS Diluted:	-0.384

Trade AMAG NOW!

The Latest On AMAG

AMAG Pharma Says Ferumoxytol Treatment Produced Significant Hemoglobin 5/21/13 8:48am

A Peek Into The Market Before The Trading Starts 3/15/13 7:20am

AMAG Announces Positive Preliminary from IDA-303 study 3/15/13 6:11am

UPDATE: JP Morgan Upgrades AMAG Pharmaceuticals to Neutral on Improving Fundamentals 3/4/13 8:27am

AMAG Pharmaceuticals Update Announces Preliminary 2012 Financial Results and 2013 Financial Guidance 1/6/13 1:34pm

AMAG Pharma Names Greg Madison Chief Commercial Officer 1/2/13 9:45am

AMAG Pharma Submits Supplemental NDA for Feraheme 12/24/12 9:32am

AMAG Pharma Reports New Data from Ferumoxytol Pivotal Phase III Broad Iron Deficiency Anemia Program 12/10/12 12:17pm

Rienso Receives Swiss Marketing Authorization for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease 9/5/12 8:17am

Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Cash 8/2/12 1:05am

Financial Breakfast: Morning News Summary for July 18, 2012 7/18/12 7:20am

AMAG Pharmaceuticals Announces Positive Preliminary Results from its Phase III Study Evaluating Feraheme Compared to Placebo in Patients with Iron Deficiency Anemia 7/18/12 6:48am

Press Releases

Ferumoxytol Treatment Produced Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Gastrointestinal Disease Who Had Failed or Could Not Tolerate Oral Iron Therapy 5/21/13 GlobeNewswire

Ferumoxytol Results in Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed or Could Not Tolerate Oral Iron Therapy 5/6/13 GlobeNewswire

AMAG Pharmaceuticals to Present at the Needham Healthcare Conference 4/26/13 Business Wire

AMAG Announces First Quarter 2013 Financial Results 4/23/13 Business Wire

AMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013 4/19/13 Business Wire

AMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause 3/15/13 Business Wire

AMAG Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Feraheme Label Expansion to Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron 3/6/13 Business Wire

AMAG Announces Fourth Quarter and Year End 2012 Financial Results 3/1/13 Business Wire

AMAG Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences 2/21/13 Business Wire

AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference 2/7/13 Business Wire

AMAG Pharmaceuticals Provides Business Update Announces Preliminary 2012 Financial Results and 2013 Financial Guidance 1/6/13 Business Wire

AMAG Pharmaceuticals Appoints Greg Madison as Chief Commercial Officer 1/2/13 Business Wire

Get the latest AMAG stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for AMAG Pharmaceuticals, Inc. stock price.

Partner Headlines

AMAG Narrows Loss; Maintains View - Analyst Blog 4/24/13

Positive Results on AMAG's Feraheme - Analyst Blog 3/18/13

FDA Action Date for AMAG Drug - Analyst Blog 3/11/13

AMAG Narrows Loss, Maintains View - Analyst Blog 3/4/13

AMAG Gives 4Q12 Snapshot - Analyst Blog 1/7/13

AMAG Pharmaceuticals, Inc. (AMAG) EVP, COO Frank E Thomas sells 10,000 Shares 1/4/13

AMAG Seeks Feraheme Label Expansion - Analyst Blog 12/27/12

AMAG Presents Feraheme Data - Analyst Blog 12/11/12

AMAG Pharmaceuticals Inc. (AMAG) EVP, COO Frank E Thomas sells 5,000 Shares 12/4/12

AMAG Pharmaceuticals, Inc. (AMAG) EVP, COO Frank E Thomas sells 5,000 Shares 12/4/12